Page 27 - Vaccine

Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy

In India, Wockhardt aims to make 2 billion doses of Covid-19 vaccines within the next one or two years but has not disclosed the identity of the tie-ups

Covid-19 vaccination: Govt books 440 million doses with 30% advance

250 mn Covishield and 190 mn Covaxin doses meant for Aug-Dec period

Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals

The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145

Ocugen pays $15 mn upfront to Bharat Biotech for Covaxin rights in Canada

Ocugen Inc, the US partner for Bharat Biotech's Covid-19 vaccine has announced the payment of $ 15 million upfront to the Indian drug maker for extending the vaccine rights to Canada

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

Free Covid-19 vaccine for all above 18 years from June 21: PM Modi

Of the total vaccine availability, 75 per cent will be procured by the Centre and the remaining 25 per cent will continue to be available for private hospitals.

Course correction on vaccine

Transparent supply formula must accompany central procurement

UP, Maharashtra may bear maximum cost of Covid-19 vaccination: Analysts

According to sources in companies, vaccine makers get regular queries from state governments but the distribution is done according to a quota decided by the Centre

Covishield shows better antibody response than Covaxin, says study

The study was aimed at analysing the antibody response after two complete doses of Covishield and Covaxin in Indians

Decoded: Who can get antibody cocktail for Covid-19 and how it works

Used to treat only mild to moderate disease in high-risk Covid-19 patients, doctors feel the treatment can bolster the fight against severe disease

All eyes on GoM call on taxing Covid items

Under the GST laws, hundreds of mass consumption items and essential services are exempted fully or attract a lower rate of tax than the standard rate of 18%

Explained: What if the Covid-19 virus was leaked from a laboratory

A paper published by the WHO on March 30, 2021 claimed manmade origin of the virus was "extremely unlikely". This view is now being challenged

Parents, school staff must be vaccinated for children's safety: Jacob John

John says that the world needs to start talking about eradicating Covid

For a Covid-19 vaccine, journey from lab to jab can take up to 4 months

Manufacturing alone takes 40-120 days

Working to import Pfizer Covid-19 vaccine at the earliest, says govt

Pfizer's indemnity request is also being looked into by the government

Shortage of transparency

Govt, companies must end opacity on vaccine supplies

Cyprus health authority says people under 50 should use mRNA-based vaccines

Cypriot health authorities on Wednesday advised people aged under 50 to use the Pfizer/BioNTech or Moderna vaccines that are based on the newer, mRNA technology

India administers over 200 mn Covid-19 vaccine doses till May 25

In a landmark achievement in its fight against Covid-19, India has cumulatively administered more than 200 million vaccine doses up till 7 pm on May 25

GST panel rejects demand for tax waiver on Covid-19 vax, ventilator

GST fitment panel has recommended a short-term rate cut on four Covid-19 related items

AstraZeneca Pharma India Q4 net profit up nearly 3-fold to Rs 27.27 cr

Drug firm AstraZeneca Pharma India on Tuesday reported a nearly three-fold jump in its net profit to Rs 27.27 crore for the quarter ended March 31, 2021. The company had posted a net profit of Rs 9.57 crore for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations of the company stood at Rs 210.25 crore for the quarter under consideration. It was Rs 194.90 crore for the same period a year ago, it added. For the financial year ended March this year, the net profit of the company was Rs 93.30 crore as against Rs 72.22 crore for the previous financial year, the filing said. The company's revenue from operations stood at Rs 813.56 crore for the financial year ended March 31, 2021. It was Rs 831.80 crore for the year-ago fiscal, it added. Shares of AstraZeneca Pharma India closed at Rs 3,862.45 per scrip on BSE, up 0.84 percent from its previous close.